

**Supplementary Table 1. Comparison between CSF viremic subjects and intact blood-brain barrier with versus without detectable CSF CXCL13: demographic, clinical, viro-immunological and CSF biomarkers**

Parameter	Detectable CSF CXCL13 (n=19)	Undetectable CSF CXCL13 (n=47)	P
<b>Age, years</b>	48 (38-57)	46 (39-50)	0.449
<b>Male sex, n</b>	15 (78.9%)	34 (72.3%)	0.578
<b>Caucasian, n</b>	18 (94.7%)	38 (80.8%)	0.154
<b>Exposure route, n</b>			0.617
MSM	7 (36.8%)	13 (27.6%)	
Heterosexual	7 (36.8%)	16 (34.0%)	
pIVDU	5 (26.3%)	18 (38.3%)	
<b>On cART, n</b>	7 (36.8%)	18 (38.3%)	0.912
<b>Regimen, n</b>			0.446
Dual	2/7 (28.6%)	2/18 (11.1%)	
PI-2NRTIs	0/7 (0%)	6/18 (33.3%)	
nN-2NRTIs	1/7 (14.3%)	3/18 (16.7%)	
INI-2NRTIs	1/7 (14.3%)	2/18 (11.1%)	
Others	3/7 (42.8%)	5/18 (27.8%)	
<b>Plasma HIV-RNA, Log10 cp/mL</b>	5.13 (1.60-5.83)	5.18 (1.74-5.71)	0.882
<b>Undetectable plasma HIV-RNA, n</b>	3 (15.8%)	10 (21.2%)	0.803
<b>CSF HIV-RNA, Log10 cp/mL</b>	4.17 (2.18-4.63)	2.56 (2.10-3.70)	<b>0.018</b>
<b>CSF escape, n</b>	4 (21.0%)	9 (19.1%)	0.861
<b>CD4 count, cells/mmc</b>	70 (33-194)	83 (29-282)	0.613
<b>CD4/CD8 ratio</b>	0.1 (0.1-0.2)	0.2 (0.1-0.5)	0.286
<b>CD4 nadir, cells/mmc</b>	48 (15-99)	47 (16-141)	0.502
<b>Time since HIV diagnosis, months</b>	79 (1-150)	41 (1-180)	0.810
<b>Clinical category, n</b>			0.943
Neurological complaints	2 (10.5%)	5 (10.6%)	0.968
HAND	4 (21.0%)	7 (14.9%)	0.416
Asymptomatic	8 (42.1%)	21 (44.7%)	0.849
HIV-related	5 (26.3%)	14 (29.8%)	0.740
<b>Previous syphilis, n</b>	1 (5.3%)	8 (17.0%)	0.207
<b>CSF cells</b>	0 (0-1)	0 (0-0)	0.980
<b>CSF proteins</b>	49 (35-56)	39 (29-49)	<b>0.039</b>
<b>CSF glucose</b>	51 (41-60)	53 (49-61)	0.260
<b>Tourtelotte</b>	16.4 (4.6-47.1)	5.5 (0.3-13.6)	<b>0.008</b>
<b>Tibbling</b>	1.0 (0.8-1.3)	0.8 (0.6-1.1)	0.062
<b>CSAR</b>	5.3 (3.4-6.3)	4.4 (3.2-5.9)	0.348
<b>IgG index</b>	0.55 (0.32-0.69)	0.37 (0.24-0.50)	0.616
<b>CSF synthesis, n</b>	15 (78.9%)	25 (53.2%)	<b>0.052</b>
<b>CSF % synthesis, %</b>	38.0 (30.5-50.0)	36.0 (25.0-44.0)	0.301
<b>Neopterin</b>	3.6 (0.9-9.2)	1.1 (0.9-2.1)	<0.001
<b>S100b</b>	136.9 (59.2-298.4)	129.4 (89.2-173.2)	0.704

Legend: CXCL13, C-X-C motif chemokine ligand 13; MSM, males who have sex with other males; pIVDU, previous intra-venous drug users; PI, protease inhibitor; NRTIs, nucleoside reverse transcriptase inhibitors; nNRTI, non-nucleoside reverse transcriptase inhibitor; INI, integrase strand transfer inhibitor; CSF, cerebrospinal fluid; HAND, HIV-Associated neurocognitive disorders; CNS, central nervous system; CSAR, cerebrospinal fluid-to-serum albumin ratio; S100b, S100 beta protein.

**Supplementary Table 2. Comparison between CSF controllers and intact blood-brain barrier with versus without detectable CSF CXCL13: demographic, clinical, viro-immunological and CSF biomarkers**

Parameter	Detectable CSF CXCL13 (n=9)	Undetectable CSF CXCL13 (n=71)	P
<b>Age, years</b>	54 (45-68)	50 (44-56)	0.172
<b>Male sex, n</b>	6 (66.7%)	50 (70.4%)	0.818
<b>Caucasian, n</b>	9 (100%)	63 (88.7%)	0.292
<b>Exposure route, n</b>			0.512
MSM	4 (44.4%)	31 (43.7%)	
Heterosexual	0 (0.0%)	17 (23.9%)	
pIVDU	5 (55.5%)	23 (32.4%)	
<b>Regimen, n</b>			0.902
Dual	2 (22.2%)	10 (14.1%)	
PI-2NRTIs	2 (22.2%)	26 (36.6%)	
nN-2NRTIs	2 (22.2%)	11 (15.5%)	
INI-2NRTIs	2 (22.2%)	16 (22.5%)	
Others	1 (11.1%)	8 (11.3%)	
<b>Plasma HIV-RNA, Log10 cp/mL</b>	1.28 (0.04-1.28)	1.28 (0.04-1.28)	0.688
<b>Detectable plasma HIV-RNA, n</b>	0 (0.0%)	16 (22.5%)	0.111
<b>CD4 count, cells/mmc</b>	560 (394-920)	466 (313-704)	<b>0.043</b>
<b>CD4/CD8 ratio</b>	1.2 (0.7-1.9)	0.7 (0.4-1.1)	<b>0.018</b>
<b>CD4 nadir, cells/mmc</b>	201 (49-238)	153 (50-253)	0.615
<b>Length of HIV infection, months</b>	59 (38-231)	135 (39-222)	0.814
<b>Length of plasma suppression, months</b>	29 (9-49)	26 (8-89)	0.265
<b>Time on last cART regimen, months</b>	9 (9-41)	12 (6-26)	0.142
<b>Clinical category, n</b>			<b>0.052</b>
Neurological complaints	1 (11.1%)	19 (26.8%)	0.307
HAND	6 (66.7%)	19 (26.8%)	<b>0.015</b>
Asymptomatic	2 (22.2%)	33 (46.5%)	0.167
HIV-related	0 (0.0%)	0 (0.0%)	-
<b>Previous syphilis, n</b>	3 (33.3%)	14 (19.7%)	0.350
<b>CSF cells</b>	0 (0-0)	0 (0-0)	0.758
<b>CSF proteins</b>	50 (38-58)	39 (29-47)	<b>0.034</b>
<b>CSF glucose</b>	63 (54-74)	58 (54-62)	0.131
<b>Tourtelotte</b>	2.9 (0.0-11.9)	0.0 (0.0-6.2)	<b>0.027</b>
<b>Tibbling</b>	0.8 (0.4-1.4)	0.6 (0.5-0.7)	<b>0.023</b>
<b>CSAR</b>	5.5 (3.9-6.2)	4.5 (3.2-5.8)	0.258
<b>IgG index</b>	0.37 (0.25-0.64)	0.28 (0.19-0.39)	<b>0.023</b>
<b>CSF synthesis, n</b>	6 (66.7%)	18 (25.3%)	<b>0.011</b>
<b>CSF % synthesis, %</b>	42.0 (12.0-61.0)	31.0 (19.0-50.7)	0.612
<b>Neopterin</b>	1.4 (0.6-2.5)	0.6 (0.4-1.0)	<b>0.001</b>
<b>S100b</b>	136.0 (91.4-207.9)	110.2 (69.2-183.4)	0.916

Legend: CXCL13, C-X-C motif chemokine ligand 13; MSM, males who have sex with other males; pIVDU, previous intra-venous drug users; PI, protease inhibitor; NRTIs, nucleoside reverse transcriptase inhibitors; nNRTI, non-nucleoside reverse transcriptase inhibitor; INI, integrase strand transfer inhibitor; CSF, cerebrospinal fluid; HAND, HIV-Associated neurocognitive disorders; CNS, central nervous system; CSAR, cerebrospinal fluid-to-serum albumin ratio; S100b, S100 beta protein.